Pan-cancer analyses of ANGPTL4 expression and its prognostic significance in the TCGA database. by Yu Zhang (12946)

Subjects:

Pan-cancer analyses of NFKB2 expression and its prognostic significance in the TCGA database. by Yu Zhang (12946)

Subjects:

Significant clusters: Coronal PET images showing brain regions with significant (p < 0.001 and K > 50) metabolic inhibition (A-G) and activation (H-I) in rats following cocaine sel... by Christopher Rowan (21499924)

WT data of set A398E/V and set M1425V/I pooled for better comparison. by Yousra El Ghaleb (22075892)

S1 File - Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic by Jelena Filimonovic (22305307)

Subjects:

Characteristics of the included studies. by Xin Liu (43569)

Subjects:

Summary of results. by Xin Liu (43569)

Subjects:

Anion-Assisted Glycosylation of Galactose: A Computational Study by Kerli Tali (22769704)

Subjects:

Bias risk assessments for each RCT study. by Xin Liu (43569)

Subjects:

The flow chart of studies selecting. by Xin Liu (43569)

Subjects:

Funnel plots for intraoperative blood loss. by Xin Liu (43569)

Subjects:

Bias risk assessments for each RCS study. by Xin Liu (43569)

Subjects:

Distinct effects on calcium channel activation of <i>CACNA1I</i> disease-associated amino acid substitutions A398E/V and M1425V/I. by Yousra El Ghaleb (22075892)

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”